Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC–ALK gene fusion

Documenti analoghi

• Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy
  di: Masanaka Sugiyama, et al.
  Pubblicazione: (2024)
• Sustained Remission Off‐Therapy in a Case of Infantile ALK‐Positive Multisystem Histiocytosis Treated With Crizotinib
  di: Saba Azarnoush, et al.
  Pubblicazione: (2025)
• Successful treatment of pediatric mature B‐cell lymphoma with MYC and BCL6 rearrangements
  di: Ryo Hamada, et al.
  Pubblicazione: (2025)
• The AYA gap for rhabdomyosarcoma
  di: Simone Hettmer, et al.
  Pubblicazione: (2024)
• Novel mutation in KIF23 causing congenital dyserythropoietic anemia type III in patients who underwent allogeneic hematopoietic stem cell transplantation
  di: Tomoko Fujikawa, et al.
  Pubblicazione: (2024)